Of mice and men: pathophysiology of male osteoporosis

Journal of Men's Health and Gender

Volumn 4, Issue 1, 2007, Pages 87-93

  Patsch, Janina ^a,b   Muschitz, Christian ^b   Resch, Heinrich ^b   Pietschmann, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b St Vincent Hospital   (Austria)

Author keywords

Gender; Osteoporosis in men; Pathophysiology

Indexed keywords

ANDROGEN; AROMATASE; COLLAGEN TYPE 1; GLYCOSYLCERAMIDASE; LACTASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; SEX HORMONE; SOMATOMEDIN C; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; BONE DENSITY; BONE REMODELING; BONE STRENGTH; CALCIUM INTAKE; DNA POLYMORPHISM; FAMILY HISTORY; FRACTURE; GENETIC SUSCEPTIBILITY; GENETICS; GEOMETRY; HUMAN; LIFESTYLE; MEDICAL RESEARCH; MEN'S HEALTH; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RODENT; SEX DIFFERENCE; TRABECULAR BONE; VITAMIN D DEFICIENCY;

EID: 33847633948     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2006.05.010     Document Type: Article

References (58)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy. J Am Med Assoc 285 (2001) 785-795
2. Gillberg P., Johansson A.G., and Ljunghall S. Decreased estradiol levels and free androgen index and elevated sex hormone-binding globulin levels in male idiopathic osteoporosis. Calcif Tissue Int 64 (1999) 209-213
3. Pietschmann P., Kudlacek S., Grisar J., et al. Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31 (2001) 444-451
4. Schiller C., Gruber R., Redlich K., et al. 17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures. Endocrinology 138 11 (1997) 4567-4571
5. Pfeilschifter J., Koditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23 (2002) 90-119
6. Shaughnessy S.G., Walton K.J., Deschamps P., Butcher M., and Beaudin S.M. Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. Cytokine 20 (2002) 78-85
7. Braidman I., Baris C., Wood L., et al. Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis. Bone 26 5 (2000) 423-427
8. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., and Qin K. Aromatse deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80 (1995) 3689-3698
9. Smith E.P., Boyd J., Frank G.R., et al. Estrogen resistance caused by a mutation in the estrogen receptor-gene in a man. N Engl J Med 331 (1994) 1056-1061
10. Saito H., and Yanaihara T. Steroid formation in osteoblast-like cells. J Int Med Res 26 (1998) 1-12
11. Van der Eerden B.C., Van de Ven J., Lowik C.W., Wit J.M., and Karperien M. Sex steroid metabolism in the tibial growth plate of the rat. Endocrinology 143 (2002) 4048-4055
12. Vanderschueren D., Van Herck E., Suiker A.M.H., et al. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res 8 (1993) 801-809
13. Marcus R., Leary D., Schneider D.L., et al. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 85 (2000) 1032-1037
14. Wakley G.K., Schutte H.D.J., Hannon K.S., et al. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J Bone Miner Res 6 4 (1991) 325-330
15. Tobias J.H., Gallagher A., and Chambers T.J. 5-α dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats. Am J Physiol 267 (1994) E853-E859
16. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 359 9320 (2002) 1841-1850
17. Matsumoto C., Inada M., Toda K., and Miyaura C. Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity. Bone 38 (2006) 220-226
18. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 359 9320 (2002) 1841-1850
19. Aaron J.E., Makins N.B., and Sagreiy K. The microanatomy of trabecular bone loss in normal ageing men and women. Clin Orthop 215 (1987) 260-271
20. Frost H.M. The mechanostat: a proposed pathogenetic mechanism of osteoporosis and the bone mass effects of mechanical and non-mechanical agents. Bone Miner 2 (1987) 73-85
21. Kudlacek S., Schneider B., Peterlik M., et al. Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest 33 (2003) 323-331
22. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111 (2003) 1221-1230
23. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
24. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., and Willvonseder R. Serum levels of osteoprotegerin increase with age an a healthy adult population. Bone 32 (2003) 681-686
25. Yano K., Tsuda E., Washida N., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14 4 (1999) 518-527
26. Schett G., Kiechl S., Redlich K., et al. Soluble RANKL and risk of nontraumatic fracture. J Am Med Assoc 291 9 (2004) 1108-1113
27. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 9 (1998) 1260-1268
28. Kiel D.P., Kauppila L.I., Cupples L.A., Hannan M.T., O'Donnell C.J., and Wilson P.W. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 68 5 (2001) 271-276
29. Ziegler S., Kudlacek S., Luger A., and Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182 1 (2005) 175-180
30. Gori F., Hofbauer L.C., Conover C.A., et al. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinol 140 (1999) 5579-5586
31. Ljunghall S., Johansson A.G., Burman P., Kämpe O., Lindh E., and Karlsson F.A. Low plasma levels of insulin-like growth factor (IGF-1) in male patients with idiopathic osteoporosis. J Int Med 232 (1992) 59-64
32. Patel M.B.R., Arden N.K., Masterson L.M., et al. Investigating the role of the growth hormone-insulin-like growth factor (GH-IGF) axis as a determinant of male bone mineral density (BMD). Bone 37 (2005) 833-841
33. Sezer O., Heider U., Zavrski I., Kuhne C.A., and Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101 6 (2003) 2094-2098
34. Fahrleitner A., Prenner G., Kniepeiss D., et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. Wien Klin Wochenschr 114 15-16 (2002) 717-724
35. Fahrleitner A., Prenner G., Leb G., et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 32 1 (2003) 96-106
36. Kerschan-Schindl K., Strametz-Juranek J., Heinze G., et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant 22 8 (2003) 843-850
37. Pietschmann F., Breslau N.A., and Pak C.Y. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 7 12 (1992) 1383-1388
38. Resch H., Pietschmann P., Woloszczuk W., Krexner E., Bernecker P., and Willvonseder R. Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest 22 8 (1992) 542-545
39. Grant S.F., Reid D.M., Blake G., et al. Reduced bone density and osteoporosis associated with a polymorphic Sp1 site in the collagen type I alpha 1 gene. Nat Genet 14 (1996) 203-205
40. Uitterlinden A.G., Burger H., Huang Q., et al. Relation of alleles of the collagen type I α 1 gene to bone density and risk of osteoporotic fractures in postmenopausal women. N Eng J Med 338 (1998) 1016-1022
41. Mann V., and Ralston S.H. Meta-analysis of COLIA1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone 32 (2003) 711-717
42. Efstathiadou Z., Tsatsoulis A., and Ioannidis J.P. Association of I alpha 1 Sp1 polymorphism with the risk of prevalent fractures: a meta-analysis. J Bone Miner Res 16 (2001) 1586-1592
43. Ralston S.H., Uitterlinden A.G., Brandi M.L., et al. Large-scale evidence for the effect of the COLIA Sp1 polymorphisms on osteoporosis outcomes: the GENOMOS study. PLoS Med 3 4 (2006) e90 [E-pub 2006 Feb 21]
44. Kanan R.M., Varanasi S.S., Francis R.M., Parker L., and Datta H.K. Vitamin D receptor gene start codon polymorphism (FokI) and bone mineral density in healthy male subjects. Clin Endocrinol (Oxford) 53 1 (2000) 93-98
45. Ferrari S., Manen D., Bonjour J.P., Slosman D., and Rizzoli R. Bone mineral mass and calcium and phosphate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 84 6 (1999) 2043-2048
46. Lorentzon M., Swanson C., Eriksson A.L., Mellstrom D., and Ohlsson C. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J Bone Miner Res 21 2 (2006) 332-339
47. Rosen C.J., Kurland E.S., Vereault D., et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83 7 (1998) 2286-2290
48. Gugatschka M., Dobnig H., Fahrleitner-Pammer A., et al. Molecularly-defined lactose malabsorption, milk consumption and anthropometric differences in adult males. Q J Med 98 (2005) 857-863
49. Ferrari S.L., Deutsch S., Baudoin C., et al. LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 37 6 (2005) 770-775
50. Delaney M.F. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 194 Suppl. 2 (2006) S12-S23
51. McKevith B. Diet and healthy ageing. J Br Menopause Soc 11 4 (2005) 121-125
52. Ruffing J.A., Cosman F., Zion M., et al. Determinants of bone mass and bone size in a large cohort of physically active young adult men. Nutr Metab (Lond) 3 1 (2006) 14
53. De Laet C., Kanis J.A., Oden A., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16 11 (2005) 1330-1338
54. Castro J., Toro J., Lazaro L., Pons F., and Halperin I. Bone mineral density in male adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 41 5 (2002) 613-618
55. Laitinen K., and Välimäki M. Alcohol and bone. Calcif Tissue Int 49 (1991) S70-S73
56. Laitinen K., Lamberg-Allardt C., Tunninen R., Karonen S.L., Ylikahri R., and Valimaki M. Effects of 3 weeks' moderate alcohol intake on bone and mineral metabolism in normal men. Bone Miner 13 2 (1991) 139-151
57. Laitinen K., Lamberg-Allardt C., Tunninen R., et al. Transient hypoparathyroidism during acute alcohol intoxication. N Eng J Med 324 11 (1991) 721-727
58. Lalor B.C., France M.W., Powell D., Adams P.H., and Counihan T.B. Bone and mineral metabolism and chronic alcohol abuse. Q J Med 59 229 (1986) 497-511